Sales to outside customers increased significantly to 12,231 million yen
(up 18.8% year-on-year).
Sales of the mainstay anti-inflammatory analgesic products continued to
perform well and contributed to the increase in sales. "Hadalabo Tokyo"
also performed well in the UK and key countries in the Eastern Europe and
the Middle East. In addition, ROHTO Dry Aid, a dry eye ophthalmic solution
that was launched in May 2021 after obtaining the CE marking, with which
the Company continues to develop the eye drop market, performed well.
Segment profit (operating profit basis) increased significantly to 978
million yen (up 73.6% year-on-year) due to efficient use of selling, general
and administrative expenses, despite deterioration of the cost of sales
ratio due to higher energy costs and increased procurement costs of raw
materials.